{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:42:53Z","timestamp":1784029373995,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T00:00:00Z","timestamp":1527120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010875","name":"Amgen Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jacl.2018.05.007","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T12:50:31Z","timestamp":1526993431000},"page":"1199-1207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study"],"prefix":"10.1016","volume":"12","author":[{"given":"Daniel","family":"Gaudet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisle","family":"Langslet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel S.","family":"Gidding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse K.","family":"Luirink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ruzza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ransi","family":"Somaratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick J.","family":"Raal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Wiegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2018.05.007_bib1","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2018.05.007_bib2","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"2863","article-title":"Familial hypercholesterolemia","author":"Goldstein","year":"2001"},{"issue":"3","key":"10.1016\/j.jacl.2018.05.007_bib3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijcard.2013.11.025","article-title":"Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation","volume":"171","author":"Watts","year":"2014","journal-title":"Int J Cardiol"},{"issue":"10","key":"10.1016\/j.jacl.2018.05.007_bib4","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1161\/CIRCULATIONAHA.116.023942","article-title":"Diagnosis and management of individuals with heterozygous familial hypercholesterolemia: too late and too little","volume":"134","author":"Hovingh","year":"2016","journal-title":"Circulation"},{"issue":"36","key":"10.1016\/j.jacl.2018.05.007_bib5","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacl.2018.05.007_bib6","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jacl.2011.03.453","article-title":"National Lipid Association Expert Panel on Familial Hypercholesterolemia. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Daniels","year":"2011","journal-title":"J Clin Lipidol"},{"issue":"Suppl 5","key":"10.1016\/j.jacl.2018.05.007_bib7","first-page":"S213","article-title":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report","volume":"128","year":"2011","journal-title":"Pediatrics"},{"issue":"11","key":"10.1016\/j.jacl.2018.05.007_bib8","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jacc.2009.10.042","article-title":"Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia","volume":"55","author":"Avis","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2018.05.007_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1161\/CIRCRESAHA.114.301430","article-title":"Carotid intima-media thickness in children with familial hypercholesterolemia","volume":"114","author":"Kusters","year":"2014","journal-title":"Circ Res"},{"issue":"9406","key":"10.1016\/j.jacl.2018.05.007_bib10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(04)15467-6","article-title":"Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia","volume":"363","author":"Wiegman","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jacl.2018.05.007_bib11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.292.3.331","article-title":"Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial","volume":"292","author":"Wiegman","year":"2004","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jacl.2018.05.007_bib12","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1161\/HYPERTENSIONAHA.109.192639","article-title":"Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association","volume":"54","author":"Urbina","year":"2009","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.jacl.2018.05.007_bib13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1161\/CIRCULATIONAHA.116.025158","article-title":"Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)","volume":"136","author":"Braamskamp","year":"2017","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacl.2018.05.007_bib14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacl.2015.07.011","article-title":"Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: results from the CHARON study","volume":"9","author":"Braamskamp","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"3 Suppl","key":"10.1016\/j.jacl.2018.05.007_bib15","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.jacl.2013.03.004","article-title":"Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction","volume":"7","author":"Davidson","year":"2013","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2018.05.007_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pcad.2015.04.004","article-title":"Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy","volume":"58","author":"Joseph","year":"2015","journal-title":"Prog Cardiovasc Dis"},{"issue":"18","key":"10.1016\/j.jacl.2018.05.007_bib17","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jacl.2018.05.007_bib18","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jacl.2018.05.007_bib19","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"issue":"9965","key":"10.1016\/j.jacl.2018.05.007_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jacl.2018.05.007_bib21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S2213-8587(17)30044-X","article-title":"Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study","volume":"5","author":"Raal","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6807","key":"10.1016\/j.jacl.2018.05.007_bib22","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group","volume":"303","year":"1991","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jacl.2018.05.007_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0002-9149(93)90155-6","article-title":"Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics","volume":"72","author":"Williams","year":"1993","journal-title":"Am J Cardiol"},{"issue":"39","key":"10.1016\/j.jacl.2018.05.007_bib25","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2018.05.007_bib26","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3389\/fpsyg.2015.00704","article-title":"The nature and rate of cognitive maturation from late childhood to adulthood","volume":"6","author":"Cromer","year":"2015","journal-title":"Front Psychol"},{"issue":"4","key":"10.1016\/j.jacl.2018.05.007_bib27","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni procedure for multiple tests of significance","volume":"75","author":"Hochberg","year":"1988","journal-title":"Biometrika"},{"issue":"2","key":"10.1016\/j.jacl.2018.05.007_bib28","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jpeds.2015.05.006","article-title":"Efficacy and safety of pitavastatin in children and adolescents at high future cardiovascular risk","volume":"167","author":"Braamskamp","year":"2015","journal-title":"J Pediatr"},{"issue":"17","key":"10.1016\/j.jacl.2018.05.007_bib29","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1161\/01.CIR.0000035247.42888.82","article-title":"Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin","volume":"106","author":"de Jongh","year":"2002","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacl.2018.05.007_bib30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0022-3476(03)00186-0","article-title":"Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial","volume":"143","author":"McCrindle","year":"2003","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.jacl.2018.05.007_bib31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/jama.281.2.137","article-title":"Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial","volume":"281","author":"Stein","year":"1999","journal-title":"JAMA"},{"issue":"25 Pt A","key":"10.1016\/j.jacl.2018.05.007_bib32","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.jacc.2014.04.009","article-title":"Curing atherosclerosis should be the next major cardiovascular prevention goal","volume":"63","author":"Robinson","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jacl.2018.05.007_bib33","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1592\/phco.23.7.871.32720","article-title":"Statin-associated memory loss: analysis of 60 case reports and review of the literature","volume":"23","author":"Wagstaff","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacl.2018.05.007_bib34","series-title":"FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs","year":"2012"},{"issue":"18","key":"10.1016\/j.jacl.2018.05.007_bib35","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/jama.1995.03520420045036","article-title":"Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol. The Dietary Intervention Study in Children (DISC). The Writing Group for the DISC Collaborative Research Group","volume":"273","year":"1995","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jacl.2018.05.007_bib36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.atherosclerosis.2014.05.917","article-title":"Markers of atherosclerotic development in children with familial hypercholesterolemia: a literature review","volume":"235","author":"Narverud","year":"2014","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.jacl.2018.05.007_bib37","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1185\/030079906X148472","article-title":"Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies","volume":"22","author":"Bots","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"23","key":"10.1016\/j.jacl.2018.05.007_bib38","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1161\/01.CIR.98.23.2580","article-title":"Usefulness of electron beam tomography in adolescents and young adults with heterozygous familial hypercholesterolemia","volume":"98","author":"Gidding","year":"1998","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.jacl.2018.05.007_bib39","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.290.17.2277","article-title":"Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study","volume":"290","author":"Raitakari","year":"2003","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.jacl.2018.05.007_bib40","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1001\/jama.290.17.2271","article-title":"Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study","volume":"290","author":"Li","year":"2003","journal-title":"JAMA"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418302198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418302198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:33:53Z","timestamp":1761831233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287418302198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1933287418302198"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2018.05.007","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2018.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}